Trace Biosciences received FDA IND clearance for LGW16‑03 (Nervetrace Dx), a nerve‑specific fluorescent imaging agent, enabling a first‑in‑human study to evaluate safety and intraoperative performance. The IND opens the door to clinical testing of a targeted intraoperative probe designed to help surgeons visualize peripheral nerves and reduce iatrogenic nerve injury. If the imaging agent proves safe and effective, it could become a tool to improve surgical outcomes and reduce complications across specialties that risk nerve damage. The trial’s readout will inform commercial and partnership prospects for intraoperative molecular imaging in surgical settings.